Leukemia: all 5,475 studies
Page 26 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT04156256Early Phase 1
- A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1
- Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
- CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT04154709Phase 1
- Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia PatientsStatus unknownNCT04150471
- Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
- Physical Activity Adapted at Home Supervised by Videoconferencing in Post-cancer for Children / AYA Treated for Leukemia (ONCOPED SAPATIC)TerminatedNCT04136665Not applicable
- Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid LeukemiaStatus unknownNCT04133220
- A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
- Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaWithdrawnNCT04106076Phase 1
- Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)Active, not recruitingNCT04105530Not applicable
- Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular ResponseStatus unknownNCT04104035
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedNCT04102150Phase 2
- Children and Adolescents With Leukemia, Brain Tumors, and SarcomasCompletedNCT04101123
- A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT04100330Phase 2
- Immunotherapy With CD19 CAR T-cells for B-Cell LeukemiaStatus unknownNCT04100187Phase 1
- Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate ChemotherapyStatus unknownNCT04096846
- Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic LeukemiaWithdrawnNCT04094766Phase 1
- Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeStatus unknownNCT04094051
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)TerminatedNCT04093505Phase 3
- Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young AduCompletedNCT04092803Not applicable
- FoxO3a and PU.1 in Acute Lymphoblastic LeukemiaStatus unknownNCT04092348
- Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
- Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary CaregiversActive, not recruitingNCT04090619
- A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life SettingCompletedNCT04089839
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
- Immunophenotyping of Acute b Cell Lymphoblstic LeukemiaStatus unknownNCT04084327
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
- Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory LeukaemiaCompletedNCT04082286Phase 1
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedNCT04075747Phase 1
- Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2Status unknownNCT04070807
- IA14 Induction in Young Acute Myeloid LeukemiaStatus unknownNCT04069208Phase 2
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04067336Phase 1/2
- Randomized Clinical Study Assessing Haplo vs. URD in AMLTerminatedNCT04067180Not applicable
- A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based AssessmentStatus unknownNCT04059081Phase 2
- Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/LymphomaStatus unknownNCT04055558
- The SMART CART Study: Health Information TechnologyCompletedNCT04051216Not applicable
- Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell TransplantTerminatedNCT04044560Phase 2
- Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04043676Phase 2
- CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.Status unknownNCT04037566Phase 1
- Treatment of Leukemia and Lymphoma in Children With Ataxia TelangiectasiaStatus unknownNCT04037189
- CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Early Phase 1
- TCDαβ/CD45RA Haploidentical Transplantation in Children With LeukemiaStatus unknownNCT04033627Not applicable
- Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingNCT04027309Phase 3
- Cardiovascular Effects of CART Cell TherapyCompletedNCT04026737
- Medium Dose of Cytarabine and MitoxantroneStatus unknownNCT04024241
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic LeukemiaCompletedNCT04015882Not applicable
- ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and LymphomaStatus unknownNCT04014894Phase 1
- Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.Status unknownNCT04014881Phase 1
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaWithdrawnNCT04013880Phase 1/2
- Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04012879Phase 1
- Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid LeukaemiaStatus unknownNCT04008381Phase 1
- AML Expressive WritingTerminatedNCT04006496Not applicable
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute LeukemiasStatus unknownNCT04000698Phase 3
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
- Outcome Following Truncation of AsparaginaseCompletedNCT03987542
- Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic LeukaemiaCompletedNCT03985826
- The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family PerspectivesWithdrawnNCT03985215
- CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
- Allogeneic Donor Lymphocyte Infusions Combined With BlinatumomabWithdrawnNCT03982992Phase 2
- Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCTStatus unknownNCT03977103Phase 2
- To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time FramesStatus unknownNCT03975205Early Phase 1
- Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsActive, not recruitingNCT03974217Phase 1
- Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic LeukemiaStatus unknownNCT03971565
- Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT03964259Phase 1
- Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLActive, not recruitingNCT03962465Phase 1
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
- INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTSStatus unknownNCT03955848Not applicable
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedNCT03951961Phase 2
- RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantationTerminatedNCT03948529Phase 2
- Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceWithdrawnNCT03943342Phase 2
- Nilotinib for First-line Newly Diagnosed CML-CP PatientsStatus unknownNCT03942094Phase 3
- Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.CompletedNCT03939234Phase 2
- Strength Training and ADLs in Childhood Leukemia and Lymphoma PatientsCompletedNCT03934060Not applicable
- Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any DoseActive, not recruitingNCT03933852
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSActive, not recruitingNCT03927261Phase 1
- Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance TherapyStatus unknownNCT03920813Phase 4
- Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALLCompletedNCT03919526Phase 1
- MIF Involvement in AMLActive, not recruitingNCT03918655
- A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
- Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AMLStatus unknownNCT03913312Phase 1/2
- Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyStatus unknownNCT03910842Early Phase 1
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLWithdrawnNCT03904069Phase 1
- Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75CompletedNCT03902665Phase 2
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT03900598Phase 1
- ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and LymphomaStatus unknownNCT03895944Early Phase 1
- SRSF2 Gene Mutation in Patients With t-MDS/AMLCompletedNCT03894852
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)WithdrawnNCT03888534Phase 1
- Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell AllograftStatus unknownNCT03887156Phase 2/3